Resverlogix Scientific Data Presented at EAS Congress

New data from Phase 1b/2a Trial Included

HAMBURG and CALGARY, Canada, June 22, 2010 - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced
today that key scientific data was communicated in an oral presentation
highlighting the novel features of the Company's lead drug RVX-208 at the
European Atherosclerosis Society Congress (EAS) conference being held in
Hamburg, Germany. The presentation titled "RVX-208 given orally raises
plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman
Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients
with low HDL/Apo-Al benefit most. For those patients in the highest risk
category, subjects with low baseline HDL/Apo-Al, our data demonstrated that
RVX-208 increased plasma levels of Apo-Al in the order of 13.25% compared to
placebo. This data, combined with similar low baseline HDL/Apo A-l data
analysis of the upcoming ASSERT trial data will further support the design of
a very effective and efficient ASSURE trial," said Donald J. McCaffrey,
President & CEO of Resverlogix.

Resverlogix recently completed a Phase 2 clinical trial called ASSERT to
study RVX-208 an oral small molecule therapy for the treatment of
atherosclerosis. The ASSERT trial enrolled subjects with stable coronary
artery disease. A second planned Phase 2 trial, designated ASSURE, will
include subjects with acute coronary syndrome and coronary artery disease of
whom all will be examined with intravascular ultrasound (IVUS). Both the
ASSERT and ASSURE studies are chaired by Dr. Steven Nissen, MD, Chairman of
the Cleveland Clinic Department of Cardiovascular Medicine and the principal
investigator is Dr. Stephen Nicholls, Medical Director of Intravascular
Ultrasound at the Cleveland Clinic.

Cardiovascular disease is the leading cause of death in the US and other
developed nations costing the American health care system an estimated
USD$448.5 billion in 2008. According to the American Heart Association's
Heart Disease & Stroke Statistics 2010 publication, approximately every 25
seconds an American will have a coronary event and approximately every
minute, someone will die from such an event. A key underlying cause of
cardiovascular disease is atherosclerosis, a build-up of plaque in the
arteries often referred to as 'hardening of the arteries'.

Apolipoprotein A-I (ApoA-I), the main protein component of high-density
lipoprotein (HDL), represents the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that within the atherosclerotic plaques of
the vessel wall to the liver for processing and excretion. In multiple human
and animal studies over-expression or repeated infusion of ApoA-I inhibit
progression and induce regression of atherosclerosis in animals and humans.
Developing small molecules that increase ApoA-I would satisfy a large unmet
medical need.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. The NexVas(TM) PR program is the Company's
primary focus which is to develop novel small molecules that enhance ApoA-I.
These vital therapies address the burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For
further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as
defined under applicable Canadian securities legislation, including our
statements with respect to, the current and/or future financings, research,
development and commercialization of novel therapeutics that reduce the risk
of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular diseases. These
forward-looking statements contained herein that are not based on historical
fact, including without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "continue",
"estimate", "forecasts" and other similar expressions. Our actual results,
events or developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown risks and
uncertainties including but not limited to those associated with the success
of research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval process,
competition, securing and maintaining corporate alliances, market acceptance
of the Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and additional risk
factors discussed in other documents we file from time to time with securities
authorities, which are available through SEDAR at www.sedar.com.
Additionally, risks and uncertainties are discussed in detail in the
January 31, 2010 MD&A. The forward-looking statements contained in this news
release are expressly qualified by this cautionary statement are made as of
the date hereof. The Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. The TSX Exchange does not accept responsibility for the
adequacy or accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1-403-254-9252 ext. 300, Fax: +1-403-256-8495,
Email:Theresa@resverlogix.com/

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: +1-403-254-9252 ext. 300, Fax: +1-403-256-8495, Email:
Theresa at resverlogix.com/